Medicines for Europe names a new president, the IGBA reveals its latest chair, and Chanelle and Xbrane announce fresh faces in key roles, in our latest round-up of off-patent industry appointments.
European off-patent industry association Medicines for Europe has named Stada’s head of western Europe and Germany, Stephan Eder, to become the industry body’s new president for a two-year term.
Eder – who previously headed up Stada’s businesses in Russia and the CIS and in Eastern Europe, before which he had a ten-year stint at Sandoz, as well...
Formycon said it predicted low earnings in the first quarter of 2025, after enjoying milestone payments last year. Now, the pressure is on the growing biosimilars portfolio to pull the company through this year.
Gedeon Richter’s CEO weighed in on the pricing landscape for biosimilars as the firm admitted the market for biosimilar denosumab was set to be more crowded than it had initially anticipated.
Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.
